~~<i id='97A74CF4DC'><strike id='97A74CF4DC'><tt id='97A74CF4DC'><pre id='97A74CF4DC'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

comprehensive

author：focus 2025-09-06 04:14:27 - browse：88

The FDA building -- First Opinion coverage from STAT — Adobe

The Food and Drug Administration on Thursday approved the first medicine developed specifically to treat the serious liver disease known as MASH.

The pill, called Rezdiffra, is made by Madrigal Pharmaceuticals.

Metabolic dysfunction-associated steatohepatitis, or MASH, is often associated with obesity. The accumulation of fat in the liver causes inflammation, which leads to fibrosis, or liver scarring, and can progress in more advanced stages to cirrhosis, cancer, and the need for a liver transplant.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： After decades in use, heart stents finally beat placebo

leisure time

hotspot

entertainment

leisure time

hotspot

knowledge

HealthworkersatalabinHongKongtestingforcoronavirusinMarch2022.KinCheung/APThewhollysyntheticmRNAvacc

WSS

Publishing genetic code of viruses could cause disaster

New menopause drug shows promise in relief for hot flashes

Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

Why liver experts renamed NASH to MASH, and NAFLD to MASLD

JPM 2024: Nvidia claims we're in biological revolution. Are we?

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

leisure time

comprehensive

leisure time

State Dept. review finds Biden bears some blame for Afghanistan failures

Medical school prerequisites are outdated

Medicare details structure of new drug price negotiation program

How I ended up pumping milk in a bathroom stall at JPM 2024

DIEP, the 'gold standard' of breast reconstruction, is under threat

What is STAT's opinion section for?

State Dept. review finds Biden bears some blame for Afghanistan failures

Healthy food access boosts outcomes in two studies

Novavax promises a turnaround & Lilly roils the obesity market

JPM 2024: Verve Therapeutics looks to mainstream genome editing

hotspot

Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

Study suggests Covid rebound is far more common with Paxlovid than without

New menopause drug shows promise in relief for hot flashes

Weight loss drugs should be covered by insurers, AMA says

Carbon Health diabetes program, a test of data

JPM 2024: Nvidia claims we're in biological revolution. Are we?

entertainment

leisure time

hotspot

knowledge